Since CD4+ T cells can differentiate into various subsets with distinct immune capacities, downregulating the frequencies of pathogenic Th1/Th17 populations while maximally reversing anti-inflammatory subsets is a reasonable strategy when treating MS [15]. Here, CD4 is linked to myeloid sarcoma.